• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Diclofenac epolamine (CAS No. 119623-66-4): A Comprehensive Overview in Modern Pharmaceutical Research

Diclofenac epolamine, a compound with the chemical identifier CAS No. 119623-66-4, represents a significant advancement in the field of pharmaceutical chemistry and medicinal biology. This derivative of diclofenac, a well-known nonsteroidal anti-inflammatory drug (NSAID), has garnered considerable attention due to its unique pharmacological profile and potential therapeutic applications. The compound’s molecular structure, characterized by the presence of an epolamine moiety, contributes to its distinct mechanism of action, which distinguishes it from other NSAIDs.

The pharmacological relevance of Diclofenac epolamine is underscored by its ability to modulate inflammatory pathways while exhibiting a favorable safety profile. Recent studies have highlighted its efficacy in treating chronic inflammatory conditions, such as osteoarthritis and rheumatoid arthritis, by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. Furthermore, the epolamine group enhances tissue penetration and prolongs the drug’s duration of action, making it a promising candidate for extended-release formulations.

In the realm of drug development, Diclofenac epolamine has been investigated for its potential role in addressing musculoskeletal disorders. Clinical trials have demonstrated its ability to provide sustained pain relief with minimal gastrointestinal side effects compared to traditional NSAIDs. This is attributed to its optimized pharmacokinetic properties, which allow for targeted delivery to affected areas while minimizing systemic absorption.

The structural modification of diclofenac into Diclofenac epolamine has opened new avenues in drug design. Researchers have leveraged computational modeling and high-throughput screening to refine the compound’s efficacy and reduce off-target effects. These efforts have led to the development of novel analogs with enhanced bioavailability and reduced toxicity, aligning with the growing demand for precision medicine.

Emerging research also suggests that Diclofenac epolamine may exhibit anti-proliferative and anti-angiogenic properties, making it a candidate for investigating potential applications in oncology and vascular diseases. Preclinical studies have shown promising results in inhibiting tumor growth and preventing neovascularization, although further clinical validation is necessary.

The synthesis of Diclofenac epolamine involves sophisticated chemical methodologies that ensure high purity and yield. Advanced synthetic routes have been developed to optimize the production process while adhering to stringent regulatory standards. These advancements underscore the compound’s feasibility for large-scale manufacturing and commercialization.

The regulatory landscape for Diclofenac epolamine is evolving in response to its growing clinical relevance. Regulatory agencies are closely monitoring its safety and efficacy data to ensure it meets rigorous standards before approval for broader therapeutic use. This cautious yet optimistic approach reflects the compound’s potential to address unmet medical needs while maintaining patient safety.

Future directions in Diclofenac epolamine research include exploring combination therapies with other bioactive compounds to enhance therapeutic outcomes. The integration of nanotechnology has also been proposed as a means to improve drug delivery systems, potentially revolutionizing how this compound is administered.

In conclusion, Diclofenac epolamine (CAS No. 119623-66-4) stands as a testament to the innovative strides being made in pharmaceutical chemistry. Its unique pharmacological properties, coupled with ongoing research efforts, position it as a cornerstone in modern medicinal biology. As scientific understanding continues to evolve, Diclofenac epolamine is poised to play an increasingly pivotal role in addressing complex medical challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)